Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

TIM3 antibody (AA 22-202)

TIM 3 Reactivity: Human WB, IHC (f) Host: Mouse Monoclonal unconjugated
Catalog No. ABIN7127103
  • Target See all TIM3 (TIM 3) Antibodies
    TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))
    Binding Specificity
    • 19
    • 7
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 22-202
    Reactivity
    • 68
    • 34
    • 4
    • 3
    • 2
    • 1
    Human
    Host
    • 48
    • 24
    • 22
    • 2
    Mouse
    Clonality
    • 51
    • 44
    • 1
    Monoclonal
    Conjugate
    • 57
    • 8
    • 7
    • 7
    • 7
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This TIM3 antibody is un-conjugated
    Application
    • 42
    • 40
    • 35
    • 23
    • 12
    • 8
    • 5
    • 4
    • 4
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))
    Specificity
    TIMs are type I transmembrane glycoproteins with one Ig-like V-type domain and a Ser/Thr-rich mucin stalk. TIM-3 is expressed on the surface of effector T cel tonsil, lymph node or spleen. ls (CD4+Th1 and CD8+Tc1) but not on helper T cells (CD4+Th2 and CD8+Tc2). In chronic inflammation, autoimmune disorders, and some cancers, TIM-3 is upregulated on several other hematopoietic cell types. The Ig domain of TIM-3 interacts with a ligand on resting but not activated Th1 and Th2 cells. The glycosylated Ig domain of TIM-3 binds cell-associated galectin-9. This induces TIM-3 Tyr phosphorylation and pro-apoptotic signaling. TIM-3 functions as a negative regulator of Th1 cell activity. Its blockade results in increased IFN-gamma production, Th1 cell proliferation and cytotoxicity, regulatory T cell development, and increases in macrophage and neutrophil infiltration into sites of inflammation.
    Cross-Reactivity (Details)
    Human.
    Purification
    1.0mg/ml of Ab purified from Bioreactor by Protein A/G.
    Immunogen
    Recombinant fragment of human TIM3 protein (around aa 22-202) (exact sequence is proprietary)
    Isotype
    IgG2
    Top Product
    Discover our top product TIM 3 Primary Antibody
  • Application Notes

    Known_Application: Western Blot (1-2 μg/mL),Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95 °C followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.

    Positive_Control: HepG2 or Daudi cells. Human tonsil, lymph node or spleen.

    Restrictions
    For Research Use only
  • Concentration
    1.0 mg/mL
    Buffer
    Prepared in 10 mM PBS, WITHOUT BSA and Azide.
    Preservative
    Azide free
    Storage
    -20 °C,-80 °C
    Storage Comment
    Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.
    Expiry Date
    24 months
  • Target
    TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))
    Alternative Name
    HAVCR2 (TIM 3 Products)
    Synonyms
    HAVCR2 antibody, MGC140131 antibody, HAVcr-2 antibody, KIM-3 antibody, TIM3 antibody, TIMD-3 antibody, TIMD3 antibody, Tim-3 antibody, TIM-3 antibody, Tim3 antibody, Timd3 antibody, tim3 antibody, hepatitis A virus cellular receptor 2 antibody, HAVCR2 antibody, Havcr2 antibody
    Target Type
    Virus
    Background
    CD366, HAVR2, Hepatitis A virus cellular receptor 2 (HAVCR2), Kidney injury molecule 3 (KIM3), T-cell immunoglobulin and mucin domain-containing protein 3, T-cell immunoglobulin mucin receptor 3, T-cell membrane protein 3, TIM3, TIMD3,TIM3 / HAVCR2 / CD366 (Effector T-Cell Marker)
    Cellular localisation: Cell Surface
    Molecular Weight
    60kDa
    Gene ID
    84868, 710500
    UniProt
    Q8TDQ0
    Pathways
    Regulation of Lipid Metabolism by PPARalpha, Cancer Immune Checkpoints
You are here: